Close Menu

non-small cell lung cancer

A study published this month in the Journal of Thoracic Oncology supports the usefulness of Biodesix's VeriStrat lung cancer diagnostic in monitori

By Ben Butkus
This story has been updated from a version posted Oct. 25 to include comments from a GlaxoSmithKline spokesperson.

NEW YORK (GenomeWeb News) – Biodesix today announced two partnerships to increase patient access to its VeriStrat molecular diagnostic test for non-small cell lung cancer.

NEW YORK (GenomeWeb News) – Insight Genetics has received a $193,000 grant from the National Cancer Institute to develop a companion diagnostic test, the molecular diagnostics company said today.

This article was originally posted on Sept. 1.
Roche last week said that the European Commission has approved the use of Tarceva as a first-line monotherapy for non-small cell lung cancer in patients with EGFR activating mutations.

Pages

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.